Eidogen-Sertanty Licenses Target Informatics Platform to NCBI
News Mar 10, 2006
Eidogen-Sertanty, Inc. has announced that they have licensed their Target Informatics Platform™ (TIP™) to the U.S. National Library of Medicine’s National Center for Biotechnology Information (NCBI), based in Bethesda, MD.
Under the terms of the annual license, scientists at the NCBI will have access to the TIP structural knowledgebase as well as Eidogen-Sertanty’s EVE Comparative Visualizer.
"We’re extremely pleased to be collaborating with the NCBI. They have developed a number of outstanding and widely used informatics platforms over the years, and I’m optimistic that our interaction will lead to new high impact advances," said Derek Debe, Eidogen-Sertanty’s Chief Scientific Officer.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.